Alexander N Snel
Overview
Explore the profile of Alexander N Snel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tettero J, Heidinga M, Mocking T, Fransen G, Kelder A, Scholten W, et al.
Leukemia
. 2024 Jan;
38(3):630-639.
PMID: 38272991
Measurable residual disease (MRD) measured in the bone marrow (BM) of acute myeloid leukemia (AML) patients after induction chemotherapy is an established prognostic factor. Hemodilution, stemming from peripheral blood (PB)...
2.
Ngai L, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland M, Fayed M, et al.
Blood
. 2023 Mar;
141(21):2657-2661.
PMID: 36898087
No abstract available.
3.
Ngai L, Ma C, Maguire O, Do A, Robert A, Logan A, et al.
Eur J Haematol
. 2021 May;
107(3):343-353.
PMID: 34053123
Objectives: This study aims to retrospectively assess C-lectin-like molecule 1 (CLL-1) bimodal expression on CD34+ blasts in acute myeloid leukemia (AML) patients (total N = 306) and explore potential CLL-1...
4.
Hanekamp D, Snel A, Kelder A, Scholten W, Khan N, Metzner M, et al.
Br J Haematol
. 2020 Apr;
190(6):891-900.
PMID: 32239670
Leukaemic stem cells (LSC) have been experimentally defined as the leukaemia-propagating population and are thought to be the cellular reservoir of relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements...
5.
Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham J, et al.
Leukemia
. 2018 Dec;
33(5):1102-1112.
PMID: 30542144
Current risk algorithms are primarily based on pre-treatment factors and imperfectly predict outcome in acute myeloid leukemia (AML). We introduce and validate a post-treatment approach of leukemic stem cell (LSC)...
6.
Cloos J, Harris J, Janssen J, Kelder A, Huang F, Sijm G, et al.
J Vis Exp
. 2018 Mar;
(133).
PMID: 29553571
Response criteria in acute myeloid leukemia (AML) has recently been re-established, with morphologic examination utilized to determine whether patients have achieved complete remission (CR). Approximately half of the adult patients...
7.
Terwijn M, Zeijlemaker W, Kelder A, Rutten A, Snel A, Scholten W, et al.
PLoS One
. 2014 Sep;
9(9):e107587.
PMID: 25244440
Introduction: Treatment failure in acute myeloid leukemia is probably caused by the presence of leukemia initiating cells, also referred to as leukemic stem cells, at diagnosis and their persistence after...
8.
Schuurhuis G, Meel M, Wouters F, Min L, Terwijn M, de Jonge N, et al.
PLoS One
. 2013 Nov;
8(11):e78897.
PMID: 24244383
Persistence of leukemic stem cells (LSC) after chemotherapy is thought to be responsible for relapse and prevents the curative treatment of acute myeloid leukemia (AML) patients. LSC and normal hematopoietic...
9.
Terwijn M, van Putten W, Kelder A, van der Velden V, Brooimans R, Pabst T, et al.
J Clin Oncol
. 2013 Sep;
31(31):3889-97.
PMID: 24062400
Purpose: Half the patients with acute myeloid leukemia (AML) who achieve complete remission (CR), ultimately relapse. Residual treatment-surviving leukemia is considered responsible for the outgrowth of AML. In many retrospective...